SCM
PLX icon

Sterling Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

Sterling Capital Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$983 Hold
453
– – ﹤0.01% 3100
2025
Q4 		$815 Buy
453
+284
+168% +$581 ﹤0.01% 3153
2025
Q3 		$375 Buy
169
+1
+0.6% +$2 ﹤0.01% 3181
2025
Q2 		$249 Buy
+168
New +$344 ﹤0.01% 3222

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Sterling Capital Management's PLX Position: Q1 2026 in Review

Sterling Capital Management held its Protalix BioTherapeutics (PLX) position steady in Q1 2026 at 453 shares worth $983. The position accounts for ﹤0.01% of the portfolio, ranked #3100.

Sterling Capital Management first reported a position in PLX in Q2 2025 and has held it in 4 quarters since. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Sterling Capital Management held 453 shares of Protalix BioTherapeutics worth $983 as of Q1 2026.
  • Sterling Capital Management left its Protalix BioTherapeutics share count unchanged in Q1 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #3100 holding.
  • Sterling Capital Management first reported a position in Protalix BioTherapeutics in Q2 2025 and has held it in 4 quarters since.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.